Investing
1 Coverage Fell From 72% to 60%. Is Eli Lilly’s Weight-Loss Boom Hitting an Insurance Wall?
Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward
By Omor Ibne Ehsan
Published August 28, 2026, 4:00pm ET · 2 min read
Employer coverage of GLP-1 weight-loss drugs reportedly declined from 72% in 2025 to 60% in 2026. That drop lands while Eli Lilly (NYSE:LLY | LLY Price Prediction) is still growing at scale
Second-quarter revenue reached $22.97 billion, up 47.67% year over year. Zepbound produced $4.93 billion, and Mounjaro produced $9.94 billion
Is the weight-loss boom stalling, or is it shifting shape as payers step back?
My reading is that volumes keep rising while realized prices compress. Those two outcomes read alike in headlines and behave very differently for shareholders
What the Coverage Decline Actually Shows
GLP-1 medicines mimic a gut hormone that regulates appetite and blood sugar. Zepbound is Lilly’s obesity brand and Mounjaro treats type 2 diabetes
In the US, employers finance most prescription coverage through their health plans. When they drop a category, patient out-of-pocket costs rise sharply, and prescriptions can shift toward cash-pay channels
A survey number like 60%- 72% captures stated intent. It captures what benefits managers plan to offer at renewal, while patient consumption depends on the alternatives available
Roughly 14% of surveyed employers have dropped the medicines or plan to do so in 2027. That is a signal worth taking seriously
Treat it as an early warning about affordability. Stated plans shift before renewal season closes, and reversals happen when employees complain loudly
Why Employers Are Pulling Back
Pharmacy benefits already consume about one-quarter of employer healthcare spending. GLP-1s at retail prices land on top of that base
Many employers say they have not yet seen enough savings from lower rates of diabetes, sleep apnea, and other obesity complications to justify the cost
The counterargument is straightforward. Those savings accrue over time, and annual benefit budgets do not naturally accommodate multi-year clinical payoffs
The pullback, therefore, reflects a mismatch in time horizons rather than a verdict on efficacy. It reflects how HR departments budget on annual cycles while the health payoff arrives across many years
That framing matters because it predicts what comes next. Coverage narrows where budgets are tight, and Lilly reroutes patients through cheaper direct channels
Volumes, Pricing, and Cash-Pay Verdict
Lilly’s Q2 already showed the pattern. A 60% increase in volume more than offset a 13% decrease in realized prices
Self-pay is already substantial. Approximately 45% of total Zepbound prescriptions and 55% of new Zepbound prescriptions were self-pay in the quarter
Lilly Employer Connect offers Zepbound across all doses for $449 per month through participating programs. That undercuts the sticker price employers were resisting
Add the Medicare GLP-1 Bridge Program at $50 per month out-of-pocket and state Medicaid pathways coming online. Access is broadening even where commercial coverage narrows
In essence, insurance resistance compresses price and pushes the mix toward cash and direct-to-consumer channels. It slows margin expansion without stopping volume growth, which is why LLY trades near $1,182 at a forward multiple of 34x
Contact [email protected] for any questions or corrections
Omor Ibne Ehsan
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks
All articles →
